Melanoma Clinical Trials in Houston

Showing 221-240 of 268 trials

Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma

NCT01200342

The goal of this clinical research is to learn if the combination of Genasense (oblimersen), carboplatin, and paclitaxel (GCP) can help to control metastatic uveal melanoma. The safety of this combination will also be studied.

Melanoma

M.D. Anderson Cancer Center7 participantsStarted Dec 2010

Houston, Texas, United States

COMPLETEDPhase 1< 1 mile

A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma

NCT00121680

The purpose of this study is to study the safety of E7080 administered to patients with solid tumors or lymphomas. Please note: this study is now recruiting patients with advanced and/or metastatic melanoma only. In the current phase of this study, To determine the MTD and the pharmacokinetic profile of E7080 when given as continuous daily (qd) dosing in combination with temozolomide.

Metastatic Melanoma

Eisai Inc.115 participantsStarted Jul 2005

Dallas, Texas, United States • Houston, Texas, United States

COMPLETEDPhase 1< 1 mile

Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver

NCT00833807

The goal of this clinical research is to find the highest tolerable dose of Abraxane (nab-paclitaxel) when given directly to the area where the cancer is located. The safety of this drug will also be studied.

MelanomaLiver Metastasis

M.D. Anderson Cancer Center30 participantsStarted Feb 2009

Houston, Texas, United States

Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma

A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma

Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver

Melanoma Trials in Other Cities

Phase II, 2nd Line Melanoma - RAND Monotherapy

Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia

Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma

Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation

A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma

Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma

Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma

Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma

Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma

Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Other Conditions in Houston